Roche unruffled by China bill as it looks to grow roots in the region
Endpoints News
by Ayisha Sharma
46m ago
Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in China’s pharma and diagnostics markets. Thomas Schinecker “We’ve really worked on diversifying our supply chain and this is helping us now, so that we have multiple partners to work with across the world and we can absolutely adhere to those changes in legislation, should they come,” CEO Thomas Schinecker said on a media call. In contrast, Novartis on Tuesday said it is working to shift its CRO collaborations “over time” to prepare for risks if Biosecure moves forward. The bill w ..read more
Visit website
Optum is shutting down its virtual care business
Endpoints News
by Ngai Yeung
2h ago
UnitedHealth Group’s Optum is shutting down its virtual care business, Endpoints News has learned. Known as Optum Virtual Care, the business provides online urgent and primary care visits and prescription refills and was a major part of Optum’s push into telehealth services in 2021, as Covid-19 accelerated the industry’s adoption of virtual services. The shutdown raises questions about how United is thinking about its virtual strategy. Employees in the virtual care unit were notified about the plan to shut down the business during an April 18 conference call with Optum Everycare CEO Jennifer P ..read more
Visit website
Biogen details Leqembi and Skyclarys rollouts, eyes licensing deals and sells PRV
Endpoints News
by Kyle LaHucik
2h ago
Biogen’s leaders defended their Eisai-partnered Leqembi during a first-quarter earnings update on Wednesday, saying the Alzheimer’s treatment is on a path to greater uptake as more patients started treatment last month. The company is in the midst of resetting its business, making hundreds of cuts to its workforce in recent quarters and reshaping its pipeline last year. Now, Biogen said it’s on more solid footing for the future. An increase in patients on Leqembi and better-than-anticipated sales of its rare disease drug Skyclarys buoyed Biogen’s stock, which was up about 5% $BIIB on Wednesday ..read more
Visit website
Moderna collaborates with OpenAI to use ChatGPT tech in drugmaking
Endpoints News
by Max Gelman
2h ago
Moderna has teamed up with OpenAI to bring its GPT technology to drug development. The collaboration, which a Moderna spokesperson said began in May 2023 and was not disclosed previously, has allowed the company to get up to “80% internal adoption” using a tweaked version of the popular ChatGPT, according to a press release. Moderna is now using GPTs across a variety of sections in its business. Terms of the deal will not be disclosed Wednesday, the spokesperson confirmed. In a statement, Moderna CEO Stéphane Bancel said the GPTs will help Moderna reach its goals of launching several new produ ..read more
Visit website
Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues
Endpoints News
by Jared Whitlock
3h ago
Almost 20 biopharma and life sciences companies have registered to lobby on a bill that could ban US companies from working with Chinese life sciences contractors, according to federal records. Since the Biosecure Act was introduced in January, most healthcare companies have steered away from publicly commenting on it. But as the proposal slowly advances in Congress — and as the consequences of a ban on WuXi Apptec, WuXi Biologics and genomics companies like BGI have come into focus — companies in recent months launched lobbying efforts on the bill. The list of companies that have registered t ..read more
Visit website
Centessa's public offering; Vivoryon ends Phase 2 Alzheimer’s trial
Endpoints News
by ENDPOINTS
3h ago
Plus, news about EXO Biologics: Centessa prices public offering: The startup aims to raise $93.5 million, or up to $107.6 million if all options are exercised. The funding would extend its runway into mid-2026. On Monday, Centessa announced the FDA cleared the IND for its narcolepsy program, called ORX750. A Phase 1 healthy volunteer study is set to start dosing “imminently,” with data expected in the second half of this year. — Max Gelman Vivoryon axes Ph2 Alzheimer’s trial: The German biotech is dropping the Phase 2 VIVA-MIND test of varoglutamstat in early Alzheimer’s disease after the Phas ..read more
Visit website
Samsung Bio’s bet on Plant 4 continues to pay off with first-quarter earnings growth
Endpoints News
by Anna Brown
3h ago
Samsung Biologics’ Plant 4 remains a worthwhile $2 billion investment. The CDMO said that the facility was key in its first-quarter gains and will continue to be for the rest of the year. Although the South Korean company did not break down its revenue by facility, it said on Wednesday that much of its Q1 earnings at 946.9 billion Korean won ($690 million) were due to Plant 4 — a 31% increase from the 720.9 billion Korean won ($525 million) it reported in Q1 last year. For the rest of the year, Plant 4 is forecast to boost the company’s revenue between 10% and 15%. In January, it said the faci ..read more
Visit website
A
by
ago
A ..read more
Visit website
A
by
ago
A ..read more
Visit website
A
by
ago
A ..read more
Visit website

Follow Endpoints News on FeedSpot

Continue with Google
Continue with Apple
OR